DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

2024-06-14 15:15:00

HANGZHOU, China, June 14, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that its in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, VenusP-Valve, has completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine. This momentous procedure was performed by a multidisciplinary team coordinated by Prof. Scott Lim and Prof. Michael Hainstock of the center.


This marks a significant advancement in the international progress of VenusP-Valve and represents another milestone following its CE MDR approval in April 2022.

The VenusP-Valve PROTEUS STUDY, abbreviated from Evaluation of the PerfoRmance Of The VEnUsP-Valve System in Patients with Native Right Ventricular Outflow Tract (RVOT) Dysfunction, is a prospective multi-center non-randomized interventional study in patients with RVOT disorders comorbid with moderate or greater pulmonary regurgitation. With a target enrollment of 60 subjects, data from this trial will support VenusP-Valve's registration with the U.S. FDA and Japanese Pharmaceuticals and Medical Devices Agency (PMDA).


In late 2023, the VenusP-Valve PROTEUS trial received coverage approval from the U.S. Centers for Medicare & Medicaid Services (CMS). With this endorsement, all eligible beneficiaries can be reimbursed for VenusP-Valve treatment in the study.

Following its first clinical implantation in 2013, VenusP-Valve has been applied in clinical practice for 11 years. To date, the device has been included in national health insurance programs in Germany, France, etc., and has been approved in more than fifty countries, including China, Germany, France, the United Kingdom, Italy, Spain, Canada, and Australia, with its implantation seeing continuous growth in new hospitals and centers.

"We're honored to be part of the VenusP-Valve PROTEUS trial," said Prof. Scott Lim after the procedure. "We've just completed the first patient enrollment in that trial using the VenusP-Valve. This worked quite well, and it really represents a possibility of better ways of treating patients with significant pulmonary valve disease." 

"That went really smoothly in this teenage patient with free pulmonary insufficiency", commented Prof. Michael Hainstock. "I'm very happy with the valve deployment and position. This (VenusP-Valve) is another option for our patients to treat pulmonary valve disease."

"The successful first implantation in the VenusP-Valve PROTEUS study in the U.S. represents an important milestone for Venus Medtech in this crucial market," said Lim Hou-Sen, General Manager and CEO of Venus Medtech. "The device has already received compassionate use approval from the FDA in a number of cases, underscoring its unique clinical advantages and high regulatory recognition. Moving forward, we will redouble efforts to advance VenusP-Valve's clinical progress, speeding up its approval process with both the FDA and Japan's PMDA."

About VenusP-Valve

As the first self-expanding TPVR product approved in China and Europe, VenusP-Valve carries remarkable clinical value. Uniquely designed with both flared ends, the product ensures the blood flow of branchial artery with bare stents at the outflow end. It provides a stable multi-point anchoring system and enables easy delivery, with no need for pre-stenting before the procedure. Available in a variety of specifications with extensive applicability, VenusP-Valve is able to meet the needs of 85% of patients in the case of large RVOT.

The long-term safety and efficacy of VenusP-Valve has been backed by impressive clinical data. According to three-year follow-up results of the clinical trial in Europe, the product demonstrated 100% procedural success and 0% all-cause mortality and reoperation among 81 patients who underwent TPVR. Right ventricular function improved significantly. Only one patient had severe pulmonary regurgitation.

About Venus Medtech

Venus Medtech (Hangzhou) Inc. (02500.HK) is committed to structural heart innovation. We are developing and commercializing comprehensive solutions for structural heart disease. Our robust pipeline, encompassing all four heart valves from TAVR, TPVR, TMVR, and TTVR to hypertensive renal denervation (RDN) therapy, underscores our unwavering commitment.

For more information, please visit https://www.venusmedtech.com

Contacts:

Jill Liu  
Public Relations
liujie@venusmedtech.com

Ophelia Chen
Investor Relations
chenwenjuan@venusmedtech.com

Link

PR Newswire News

2024-07-24
17:40:00
6th HK Digital Advertising Start-ups X Publishing (Writers) Promotion Support Scheme: Digital Advertising Design (for Publishing) Awards Ceremony and Sharing Session by Awardees
10:15:00
Bridge Alliance and Singtel partner to launch regional telco API exchange powered by Singtel Paragon platform
09:30:00
GreenCo's Tools and Expertise to Empower Companies to Conquer Scope 3 Emissions
2024-07-23
19:05:00
CNOOC Limited Achieved High Yield Well in Beibu Gulf
17:51:00
Guo Guangchang: Fosun Firmly Advances its Globalization Strategy
16:28:00
Sino Group and the Ng Teng Fong Charitable Foundation Support Non-Chinese Speaking Children and Promote Social Inclusion
13:00:00
Revenue Scale Continues to Expand Expected 1H 2024 Net Profit Growth over 80% YoY
04:20:00
CCSC Technology International Holdings Limited Reports Financial Results for Fiscal Year 2024
02:29:00
QMMM Holdings Limited Announces Closing of $8.6 Million Initial Public Offering
2024-07-22
19:05:00
China Literature to Report First Half 2024 Financial Results on August 12, 2024
17:14:00
NEW STUDY FINDS 50% OF HONG KONG CONSUMERS HAVE STOPPED OR CUT DOWN ON PURCHASES BECAUSE BRANDS DON'T FOCUS ON SUSTAINABILITY
17:00:00
ATFX Executive Talks: Hormoz Faryar, Managing Director of Institutional Sales, ATFX MENA
17:00:00
China Unicom Voted as "Asia's Most Honored Telecom Company" for the Ninth Consecutive Year
16:41:00
Join Hands for a Brighter Future!2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition Overseas Event (Hong Kong SAR Division) Concluded Successfully
16:07:00
From Struggles to Triumph: Weichai's Engine Technology Boosts Malaysian Fishing Vessels' Efficiency by 43%
13:21:00
EHang Partners with KC Smart Mobility to Advance EH216-S Pilotless eVTOL Sale and Operation in Hong Kong and Macau
12:32:00
Ping An Again Selected for S&P Global's Sustainability Yearbook (China Edition), the Sole Mainland Insurance Company
11:57:00
Hong Kong Seeing Dog Service(HKSEDS)6th Charity Golf Tournament 2024
09:59:00
TCL Electronics (01070.HK) Achieves 13% YoY Growth in Global TV Shipment in Q2 2024
09:00:00
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis
Back to Top